Alcamena sets out to develop the most advanced protein optimization and development platform available. We consulted with field leaders in directed evolution and conducted a world-wide search to find the best talent. The result of this effort, is a proprietary, highly refined directed evolution platform which we believe is the best on the market today. Our approach is versatile and fast, allowing us to optimize binding of peptides and proteins in a few weeks. Our strengths are directed evolution, construct design, library construction, and custom screens, including a variety of display techniques. We have the capability to develop proteins with binding affinities exceeding that of most antibodies (low pM) and/or have tissue permeability approaching that of small molecules. Our results have been independently validated in academic laboratories through jointly funded NIH projects (R43 NS105289; R43 NS110112).